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Abstract
Background: BCR-ABL kinase domain (KD) mutation is the major mechanism contributing to suboptimal response
to tyrosine kinase inhibitors (TKI) in BCR-ABL-positive chronic myeloid leukemia (CML) patients. T315I mutation, as
one of the most frequent KD mutations, has been shown to be strongly associated with TKI resistance and
subsequent therapeutic failure. A simple and sensitive method is thus required to detect T315I mutation at the
earliest stage.
Methods: A single-tube allele specific-polymerase chain reaction (AS-PCR) method was developed to detect T315I
mutation in a mixture of normal and mutant alleles of varying dilutions. Denaturing high performance liquid
chromatography (DHPLC) and direct sequencing were performed as a comparison to AS-PCR.
Results: T315I mutant bands were observed in the mixtures containing as low as 0.5-1% of mutant alleles by
AS-PCR. The detection sensitivity of DHPLC was around 1.5-3% dilution whereas sequencing analysis was unable to
detect below 6.25% dilution.
Conclusion: A single-tube AS-PCR is a rapid and sensitive screening method for T315I mutation. Detection of the
most resistant leukemic clone in CML patients undergoing TKI therapy should be feasible with this simple and
inexpensive method.
1. Background
Chronic myeloid leukemia (CML) is a chronic hemato-
poietic stem cell disorder characterized by extensive
proliferation and expansion of myeloid cells at varying
stages of maturation and differentiation [1]. The hall-
mark of CML is the Philadelphia (Ph) chromosome
which occurs as a result of a reciprocal chromosomal
translocation between chromosomes 9 and 22, creating
a new fusion gene, BCR-ABL, with constitutive tyrosine
kinase activity [2]. Targeting BCR-ABL- transfected cell
lines and murine CML models with a variety of tyrosine
kinase inhibitors (TKI) has led to a landmark discovery
of a novel BCR-ABL targeting drug, imatinib, which sub-
sequently entered clinical trials, showed significant clini-
cal benefits and has become a standard of care for CML
patients worldwide [1,3-5].
Unfortunately, failure to respond to imatinib devel-
oped in some CML patients as a result of resistant
mutations arising in the BCR-ABL kinase domain (KD),
leading to shortened survivals of CML patients with
these mutations as contrasted to those without [6-11].
The frequency of KD mutations varied from 30% to 50%
depending on the studied CML cohorts and the sensitiv-
ity and specificity of the detection methods [10-16]. The
majority of mutations in imatinib-resistant patients
usually occurred within the nine amino acid positions of
KD including G250E, Y253H/F, E255K/V, T315I,
M351T, F359V, and H396 with varying sensitivities to
TKI [17-21]. One of the most common mutations,
T315I, is associated with the most resistance to TKI,
not only to the 1
st generation TKI such as imatinib, but
also to the newly approved 2
nd generation TKI such as
nilotinib and dasatinib [9,10,17,21-23]. Screening for
T315I mutations is now recommended for all CML
patients undergoing TKI treatment and should be
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of the mutant clone [24,25].
In this study, we set out to develop a single-tube allele
specific-polymerase chain reaction (AS-PCR) to identify
the most resistant KD mutation, T315I, in Thai CML
patients. Denaturing high performance liquid chromato-
graphy (DHPLC) and sequencing analysis were also per-
formed as a comparison to AS-PCR. We found that our
method is simple, rapid, and inexpensive and thus suita-
ble for routine use, especially for CML patients residing
in the developing worlds.
2. Methods
2.1 Preparation of RNA and cDNA template
Total RNA was extracted from leukocytes using TRIzol
®
reagent (Invitrogen, CA, USA). Complementary DNA
(cDNA) was generated by SuperScript III cDNA synth-
esis kit (Invitrogen, CA, USA) following the manufac-
turer’s instructions. BA/F3 cell lines expressing the
wild-type (WT) full-length BCR-ABL fusion gene and
T315I mutant cell lines were courteously provided by
the Oregon Health & Science University [5]. RNA from
T315I mutant cell lines was serially diluted by WT
BA/F3 cells to prepare 10 dilutions with indicated
percentages of T315I mutants. Thirty RNA samples
from non-leukemic patients were also used as negative
control samples to optimize the AS-PCR condition.
2.2 Detection of T315I mutation by AS-PCR
AS-PCR was performed using three primer pairs con-
sisting of 1) T315I mutant primers, forward primer
(MT_F) (5’-GCCCCCGTTCTATATCATAAT-3’)a n d
reverse primer (MT_R) (5’-GGATGAAGTTTTT
CTTCTCCAG-3’), which was adapted from the pre-
viously published primer set [20,26], 2) the WT primers,
WT_F (5’-TGGTTCATCATCATTCAACGGTGG-3’)
and WT_R (5’-GTTCCCGTAGGTCATGAACTCAG-
3’), and 3) internal control primers, forward (b-actin_F)
(5’-gtggggcgccccaggcacca-3’)a n db-actin_R (5’-gtc
cttaatgtcacgcacgatttc-3’)[ 2 7 ] .F i r s t ,t h eA S - P C Rw a s
optimized by varying annealing temperature (Ta) (55° to
62°C), MgCl2 concentration (1.0-2.5 mmol/L), and pri-
mer ratios (MT: WT ratio of 8:2, 7:3, 6:4, and 5:5).
Briefly, the optimized condition was performed in a
25-μLm i x t u r eo f1μL cDNA, 2.5 mmol/L MgCl2,
0.2 mmol/L of each dNTP, 3% DMSO, and 0.625 unit
of Taq DNA polymerase (Invitrogen, USA) together
with 14 pmol of MT primers, 6 pmol of WT primers,
and 1 pmol of b-actin primers. The PCR profile was as
follows: initial denaturation at 95°C for 5 minutes (min),
followed by 35 cycles of denaturation at 94°C for 45 sec-
onds (sec), annealing at 57°Cf o r3 0s e c ,e x t e n s i o na t
72°C for 1 min, and final extension at 72°C for 5 min.
PCR products of T315I mutant, T315WT, and b-actin
were 158 bp, 374 bp, and 540 bp, respectively. The pro-
ducts were assessed on a 2% agarose gel and staining
with ethidium bromide. Thirty RNA sample from non-
leukemic patients were used as negative control samples
to optimize AS RT-PCR conditions for T315I.
2.3 Detection of BCR-ABL KD mutation by DHPLC and
DNA sequencing
The primary PCR step was performed using a pair of
primers designed to cover BCR-ABL gene. Two micro-
grams of cDNA template were amplified in a total
volume of 20 μL with the following constituents, 0.2 U
of high-fidelity DNA polymerase (Phusion™, FINN-
ZYME), 5X Phusion buffer, 2 mmol/L of MgCl2,
0.2 mmol/L of each dNTPs, 10 pmol of each primers
(forward primers: B2A _f 5’-acagcattccgctgaccatcaataag-3’
and reverse primer: BA_r 5’-atggtccagaggatcgctctct-’3)
[8]. The reaction mixture was placed in a thermal cycler
(Veriti, Applied Biosystems, CA) under the PCR profile
as follows: initial denaturation at 98°C for 30 sec,
35 cycles of amplification (at 98°C for 10 sec, 60°C for
30 sec, and 72°C for 1 min 30 sec), and a final extension
at 72°C for 10 min. The product band of 1,643 bp (B2A2)
or 1,719 bp (B3A2) was visualized on ethidium bromide-
stained 1.5% agarose gel. A secondary PCR step for
amplification of KD amino acid codon 206-428 using the
internal two primer pairs, were designed to amplify two
partially overlapping fragments consisting of fragment 1
forward primers: abl_1F (5’-tggttcatcatcattcaacggtgg-3’)
and reverse primers: abl_1R (5’-tctgagtggccatgtacagcagc-’3),
and fragment 2 forward primers: abl_2F (5’-tcatgacc-
tacgggaacctc-3’) and reverse primers: abl_1R (5’-atactc-
caaatgcccagacg-’3). The PCR reaction was performed in a
volume of 50 μL containing 2 μLf i r s tr o u n dP C Rp r o -
duct, 0.2 U of high-fidelity DNA polymerase, 1.5 mmol/L
of MgCl2, 0.2 mmol/L of each dNTPs, and 15 pmol of
each primers. The PCR profile was as follows: initial
denaturation at 98°C for 30 sec, 35 cycles of amplification
(98°C for 10 sec, 60°C for 30 sec, 72°C for 40 sec), and
final extension at 72°C for 5 min. The fragment 1 (447
bp) and fragment 2 (333 bp) PCR products were assessed
and prepared for furthera n a l y s i sb yD H P L Ca n d
sequencing.
Prior to DHPLC analysis, mutant products were mixed
with WT in a 1:1 ratio and denatured by heating at 95°C
for 5 min followed by gradual cooling at 1°C/min to
25°C within 70 min in order to allow heteroduplex and
homoduplex formation [28]. DNA were analyzed using a
WAVE
® nucleic acid fragment analysis system (Transge-
nomic Inc, Omaha, NA, USA) by injection of 5 to 10 μL
of each fragment onto a chromatography column (DNA-
Sep HT column, Transgenomic, USA) and were then
eluted at 59°C with a linear acetonitrile gradient in
0.1 M triethylammonium acetate buffer (TEAA) at pH 7.0.
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bance. For sequencing, the PCR products were purified
using the Qiaquick PCR purification kit (Qiagen, USA)
or ExoSAP-IT
® (GE Healthcare Bio-Sciences, USA), fol-
lowing the manufacturer’ s protocol. Sequencing with
forward and/or reverse primers in secondary PCR steps
was carried out by the ABI3730XL DNA analyzer
(Applied Biosystems, USA) using ABI BigDye terminator
cycle sequencing kits (Applied Biosystems, USA). The
results were compared with the WT ABL1 (accession no.
NM_005157.3).
Sensitivity of DHPLC and direct sequencing methods
were evaluated by determination of dilutions of known
quantities of T315I mutant products and WT products
with indicated percentages of mutant products.
3. Results
3.1. Detection of T315I mutation in dilution mixtures by
AS-PCR
AS-PCR was designed to specifically detect T315I muta-
tions using the cDNA templates synthesized from RNA
with known percentages of the mutant allele. Mutants, WT,
and internal controls could be detected in a single reaction.
We first optimized the annealing temperature and the
ratio of each primer pair and the results of our triplicate
independent experiments demonstrated that the optimal
annealing temperature was 57°C with the primers ratio of
7:3:0.5 of mutants, WT, and internal control primer
pairs, respectively. A 158-bpP C Rp r o d u c tw a sd e r i v e d
from the mutant allele whereas a 374-bp PCR product
could represent a heterozygous allele or no mutant allele
and a 540-bp product was an internal control. In three
independent experiments, a strong T315I mutant band
was detected in as low as 1% dilution and a faint band
was observed in 0.5% dilution (Figure 1). In addition, 30
samples from non-leukemic patients and WT BA/F3 cell
lines were also tested to ensure our AS-PCR’s specificity;
all of which were found negative for T315I, therefore,
BA/F3 cell lines were subsequently utilized as a T315I
negative control.
3.2 Detection of T315I in dilution mixtures by DHPLC and
sequencing
DHPLC was performed first as a screening to detect
abnormal peaks on chromatograms. The heteroduplexes
generated from the heterozygous products gave a peak
Figure 1 Sensitivity of T315I mutation detection by AS-PCR method . Serial dilutions of T315I mutants with wild-type cells demonstrates
158-bp mutant bands in 100%, 25%, 10%, 1%, and 0.5% mixtures (Figure 1A); Representative samples of T315I mutated cell lines (Lane 1), T315I
mutated CML case, (Lane 2), seven non-mutated non-leukemic cases (Lanes 3-9), and BA/F3 cell lines (Lane 10) are shown in Figure 1B; Lane 11,
blank; Lane M, a 100-bp DNA marker.
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could be clearly detected in 90%, 80%, 70%, 60%, 50%,
25%, 12.5% 6.25%, 3.13%, and 1.56% dilutions (Figure
2A). An ambiguous peak was also seen at 0.78% dilu-
tion. Prior to DHPLC analysis, PCR products were
mixed with a WT product in a 1:1 ratio to prevent the
false negative results as the homoduplexes derived from
the homozygous mutant cDNA (100%MT) generated a
sharp peak that was quite similar to the homozygous
WT peak (0% MT). T315I peak had a different peak
pattern from other common mutations (Y253F, Y253H,
E255K, M351T, and F359V) (data no shown).
For direct sequencing, a “T” peak indicated the pre-
sence of T315I which could be clearly seen in 100%,
50%, 25%, 12.5%, and 6.25%. A “C” peak which repre-
sented the WT BCR-ABL KD allele could be seen in
50%, 25%, 12.5%, 6.25%, 3.13%, and 0% dilution (100%
WT) (Figure 2B).
3.3 Detection for T315I in DHPLC and sequencing positive
patients
Nine CML patients were tested for T315 mutation using
DHPLC followed by sequencing and AS-PCR. Abnormal
DHPLC patterns strongly supportive of T315I mutation
were observed and all were confirmed by sequencing as
shown in Figure 3A. Mutant bands were comparably
seen by AS-PCR. Representative AS-PCR results of four
CML cases with abnormal DHPLC and sequencing
results (Patients no.360, no.461, no.504, and no. 509)
are shown in Figure 3B.
4. Discussion
Several methods have been utilized to detect the exis-
tence of BCR-ABL KD mutations such as direct sequen-
cing, DHPLC, restriction fragment length polymorphism
(RFLP), pyrosequencing, double-gradient denaturing
electrophoresis, AS-PCR, AS real-time PCR, array based
assays, and high-resolution melt curve analysis (HRM),
with varying sensitivity and specificity [25,26,29-35]. In
this study, we established an AS-PCR-based method to
detect T315I which is the most resistant genotype asso-
ciated with the highest impact on clinical outcome of
CML patients. The sensitivity of our AS-PCR method
was better than the sensitivities reported from most pre-
viously reported detection techniques and was slightly
better than DHPLC and direct sequencing analysis in
our hands. By AS-PCR, T315I mutant bands were
observed in the mixtures containing as low as 0.5% of
mutant alleles whereas DHPLC was unable to detect the
mutants below 1.56% dilution and sequencing was
unable to detect below 6.25%.
The detection sensitivity of DHPLC in our study was
in the range of previously published articles (1-5%)
[30,31]. Although DHPLC is considered a useful tool to
screen for the presence of either known or unknown
mutations, chromatograms generated from DHPLC were
sometimes difficult to interpret and sequencing analysis
is always needed to confirm their results. In our study,
sequencing analysis was not able to detect mutant alleles
Figure 2 Sensitivity of T315I mutation detection by DHPLC and
sequencing analysis . DHPLC chromatogram patterns generated
by each mutant allele concentration are shown in Figure 2A and
sequencing results corresponding to each DHPLC-generated
chromatogram are shown in Figure 2B; Red arrow indicates c.947
C > T mutation; C, Wild-type; T, Mutant.
Wongboonma et al. Journal of Hematology & Oncology 2011, 4:7
http://www.jhoonline.org/content/4/1/7
Page 4 of 7below the 6.25% dilution. Therefore, it is the least sensitive
method in our hands. Direct sequencing is recognized as a
confirmation method for any screening tests because of its
high specificity [25]. However, its disadvantage is its high
costs and low sensitivity (15-25%) [26], rendering it
unsuitable for routine clinical use. In terms of specificity,
all methods showed no false positive results even in our
triplicate experiments (0% mutant in the samples or 100%
WT). Our AS-PCR method had a high specificity due to
the utilization of internal mismatch primers which were
Figure 3 Detection of T315I in CML patient samples by DHPLC, sequencing and AS-PCR; Figure 3A shows DHPLC patterns followed by
sequencing analysis if a suspicious peak was observed; T315I cell lines and wild types are also shown; Figure 3B demonstrates
representative AS-PCR results of four CML cases with abnormal DHPLC and sequencing results (patients no.360, no.461, no.504, and
no. 509) .
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therefore, none of the 30 non-leukemic patient samples
were falsely found to be T315I positive.
The advantage of AS-PCR is that it does not require
additional post-PCR product preparations for the next
step as contrasted to the multiple steps such as the
DNA purification step in sequencing method and the
preparation of a 1:1 mixture of mutant and WT PCR
products followed by generation of heteroduplexes and
homoduplexes in the DHPLC method which is much
more time-consuming. AS-PCR technique can be
applied in any general laboratory worldwide. Moreover,
this present AS-PCR method could be performed in a
single tube containing all three primers for a control
gene, a WT gene, and a mutant gene; therefore, the
cDNA quality could be simultaneously assessed at the
same time of the detection of the WT and the mutant
genes. AS-PCR is also suitable to perform in cases with
a low DHPLC peak and its shape looks like a known
mutation such as T315I. The disadvantage of AS-PCR is
its ability to detect only known mutations using specific
primer sets and optimized PCR condition for each type
of mutant allele. The sensitivity of our AS-PCR method
was lower than that of Roche-Lestienne C et al [20] and
Kang HY et al [26], both of which did not use internal
b-actin control primers. Nevertheless, we believe that
the cDNA quality should be simultaneously assessed at
t h es a m et i m eo ft h ed e t e c t i o no ft h eW Ta n dt h e
mutant genes, especially in the homozygous T315I
mutant cases, therefore all three primers were utilized in
a single-tube reaction. Current clinical practice accepts a
detection method with a sensitivity of at least 0.5-1%
since a higher sensitivity may detect a clone that may
not be of clinical relevance [25,36]. Changes of TKI
therapy based on a very sensitive molecular test may
have an adverse impact if the clinical outcome is not
truly affected by the presence of a minute amount of
leukemic cells with that particular genetic defect.
5. Conclusion
Our single tube AS-PCR method is a simple, rapid, and
easy to perform test which requires only simple PCR
reagents and a PCR machine leading to overall lower
costs as compared to other more complicated and more
expensive screening methods. Detection of the most
resistant leukemic clone in CML patients undergoing
TKI therapy, especially those who reside in the develop-
ing worlds, should be feasible with this simple and inex-
pensive method. Future studies should focus on the
d e s i g no fo t h e rp r i m e rs e t st oc o v e ro t h e rm u t a t i o n s
associated with 2
nd generation TKI resistance such as
V299L/F317L in dasatinib and E255K/E255V/Y253H in
nilotinib.
Acknowledgements
WW is a graduate student in the Department of Immunology who is
supported by Siriraj Graduate Thesis Scholarship, Mahidol University. CUA is
the current recipient of the Faculty Development Award from Siriraj
Chalermprakiat Fund. The authors wish to thank Professor Brian J Druker and
Professor Michael W Deininger (Oregon Health & Science University, USA) for
their kind provision of the BCR-ABL mutated cell lines.
Author details
1Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol
University, Bangkok 10700, Thailand.
2Department of Research and
Development, Faculty of Medicine Siriraj Hospital, Mahidol University,
Bangkok 10700, Thailand.
3Department of Medicine, Faculty of Medicine
Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Authors’ contributions
WW performed the experiments and data analysis and contributed to the
drafting of the manuscript. WT performed and supervised the molecular
analysis and contributed to the revision of the manuscript. CUA was
responsible for the initiation and execution of the entire project and the
critical revision of the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 4 January 2011 Accepted: 8 February 2011
Published: 8 February 2011
References
1. Alvarez RH, Kantarjian H, Cortes JE: The biology of chronic myelogenous
leukemia: implications for imatinib therapy. Semin Hematol 2007, 44:
S4-14.
2. Groffen J, Heisterkamp N: The BCR/ABL hybrid gene. Baillieres Clin
Haematol 1987, 1:983-999.
3. Ilaria RL Jr: Animal models of chronic myelogenous leukemia. Hematol
Oncol Clin North Am 2004, 18:525-543, vii.
4. Druker BJ: Translation of the Philadelphia chromosome into therapy for
CML. Blood 2008, 112:4808-4817.
5. Druker BJ: Perspectives on the development of imatinib and the future
of cancer research. Nat Med 2009, 15:1149-1152.
6. O’Hare T, Eide CA, Deininger MW: Bcr-Abl kinase domain mutations, drug
resistance, and the road to a cure for chronic myeloid leukemia. Blood
2007, 110:2242-2249.
7. Cang S, Liu D: P-loop mutations and novel therapeutic approaches for
imatinib failures in chronic myeloid leukemia. J Hematol Oncol 2008, 1:15.
8. Ernst T, Erben P, Muller MC, Paschka P, Schenk T, Hoffmann J, Kreil S, La
Rosee P, Hehlmann R, Hochhaus A: Dynamics of BCR-ABL mutated clones
prior to hematologic or cytogenetic resistance to imatinib.
Haematologica 2008, 93:186-192.
9. Nicolini FE, Mauro MJ, Martinelli G, Kim DW, Soverini S, Muller MC,
Hochhaus A, Cortes J, Chuah C, Dufva IH, et al: Epidemiologic study on
survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic
leukemia patients with BCR-ABL T315I mutation. Blood 2009,
114:5271-5278.
10. Branford S, Melo JV, Hughes TP: Selecting optimal second-line tyrosine
kinase inhibitor therapy for chronic myeloid leukemia patients after
imatinib failure: does the BCR-ABL mutation status really matter? Blood
2009, 114:5426-5435.
11. von Bubnoff N, Schneller F, Peschel C, Duyster J: BCR-ABL gene mutations
in relation to clinical resistance of Philadelphia-chromosome-positive
leukaemia to STI571: a prospective study. Lancet 2002, 359:487-491.
12. Kim SH, Kim D, Kim DW, Goh HG, Jang SE, Lee J, Kim WS, Kweon IY,
Park SH: Analysis of Bcr-Abl kinase domain mutations in Korean chronic
myeloid leukaemia patients: poor clinical outcome of P-loop and T315I
mutation is disease phase dependent. Hematol Oncol 2009, 27:190-197.
13. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O’Brien S, Zhou X,
Luthra R, Garcia-Manero G, Giles F, et al: Frequency and clinical
significance of BCR-ABL mutations in patients with chronic myeloid
leukemia treated with imatinib mesylate. Leukemia 2006, 20:1767-1773.
Wongboonma et al. Journal of Hematology & Oncology 2011, 4:7
http://www.jhoonline.org/content/4/1/7
Page 6 of 714. Qin Y, Chen S, Jiang B, Jiang Q, Jiang H, Li J, Li L, Lai Y, Liu Y, Huang X:
Characteristics of BCR-ABL kinase domain point mutations in Chinese
imatinib-resistant chronic myeloid leukemia patients. Ann Hematol 2011,
90:47-52.
15. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O’Brien S, Garcia-Manero G,
Giles F, Breeden M, Reeves N, et al: Dynamics of BCR-ABL kinase domain
mutations in chronic myeloid leukemia after sequential treatment with
multiple tyrosine kinase inhibitors. Blood 2007, 110:4005-4011.
16. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN,
Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-
ABL gene mutation or amplification. Science 2001, 293:876-880.
17. Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Muller MC, Martinelli G,
Cortes J, Beppu L, Gottardi E, et al: Impact of baseline BCR-ABL mutations
on response to nilotinib in patients with chronic myeloid leukemia in
chronic phase. J Clin Oncol 2009, 27:4204-4210.
18. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL:
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance
to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and
blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
19. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW: Several
Bcr-Abl kinase domain mutants associated with imatinib mesylate
resistance remain sensitive to imatinib. Blood 2003, 101:4611-4614.
20. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N,
Facon T, Fenaux P, Preudhomme C: Several types of mutations of the Abl
gene can be found in chronic myeloid leukemia patients resistant to
STI571, and they can pre-exist to the onset of treatment. Blood 2002,
100:1014-1018.
21. Bradeen HA, Eide CA, O’Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ,
Deininger MW: Comparison of imatinib mesylate, dasatinib (BMS-
354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-
based mutagenesis screen: high efficacy of drug combinations. Blood
2006, 108:2332-2338.
22. Jabbour E, Kantarjian H, Cortes J: Chronic myeloid leukemia and second-
generation tyrosine kinase inhibitors: when, how, and which one? Semin
Hematol 47:344-353.
23. Wei G, Rafiyath S, Liu D: First-line treatment for chronic myeloid
leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 3:47.
24. Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Soverini S: Response
definitions and European Leukemianet Management recommendations.
Best Pract Res Clin Haematol 2009, 22:331-341.
25. Jones D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K, Press R,
Quigley N, Rothberg P, Sabath D, Viswanatha D, et al: Laboratory practice
guidelines for detecting and reporting BCR-ABL drug resistance
mutations in chronic myelogenous leukemia and acute lymphoblastic
leukemia: a report of the Association for Molecular Pathology. J Mol
Diagn 2009, 11:4-11.
26. Kang HY, Hwang JY, Kim SH, Goh HG, Kim M, Kim DW: Comparison of
allele specific oligonucleotide-polymerase chain reaction and direct
sequencing for high throughput screening of ABL kinase domain
mutations in chronic myeloid leukemia resistant to imatinib.
Haematologica 2006, 91:659-662.
27. Auewarakul CU, Huang S, Yimyam M, Boonmoh S: Natural history of
Southeast Asian chronic myeloid leukemia patients with different BCR-
ABL gene variants. Acta Haematol 2006, 116:114-119.
28. Walker JM, Rapley R, Leung KH, Yip SP: Denaturing High-Performance
Liquid Chromatography (DHPLC) for Nucleic Acid Analysis. Molecular
Biomethods Handbook Humana Press; 2008, 89-106.
29. Manrique Arechavaleta G, Scholl V, Perez V, Bittencourt R, Moellmann A,
Hassan R, Seuanez HN, Dobbin J, Martinez L, Renault IZ, Uriarte R: Rapid
and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I
mutation in chronic myeloid leukemia patients treated with tyrosine-
kinase inhibitors. Clin Exp Med 11:55-59.
30. Deininger MW, McGreevey L, Willis S, Bainbridge TM, Druker BJ,
Heinrich MC: Detection of ABL kinase domain mutations with denaturing
high-performance liquid chromatography. Leukemia 2004, 18:864-871.
31. Soverini S, Martinelli G, Amabile M, Poerio A, Bianchini M, Rosti G, Pane F,
Saglio G, Baccarani M: Denaturing-HPLC-based assay for detection of ABL
mutations in chronic myeloid leukemia patients resistant to Imatinib.
Clin Chem 2004, 50:1205-1213.
32. Ernst T, Gruber FX, Pelz-Ackermann O, Maier J, Pfirrmann M, Muller MC,
Mikkola I, Porkka K, Niederwieser D, Hochhaus A, Lange T: A co-operative
evaluation of different methods of detecting BCR-ABL kinase domain
mutations in patients with chronic myeloid leukemia on second-line
dasatinib or nilotinib therapy after failure of imatinib. Haematologica
2009, 94:1227-1235.
33. Sorel N, Chazelas F, Brizard A, Chomel JC: Double-gradient-denaturing-
gradient gel electrophoresis for mutation screening of the BCR-ABL
tyrosine kinase domain in chronic myeloid leukemia patients. Clin Chem
2005, 51:1263-1266.
34. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D,
Stoffregen EP, McWeeney S, Kovacs I, Park B, et al: High-sensitivity
detection of BCR-ABL kinase domain mutations in imatinib-naive
patients: correlation with clonal cytogenetic evolution but not response
to therapy. Blood 2005, 106:2128-2137.
35. Vivante A, Amariglio N, Koren-Michowitz M, Ashur-Fabian O, Nagler A,
Rechavi G, Cohen Y: High-throughput, sensitive and quantitative assay
for the detection of BCR-ABL kinase domain mutations. Leukemia 2007,
21:1318-1321.
36. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J,
Cervantes F, Deininger M, Gratwohl A, Guilhot F, et al: Chronic myeloid
leukemia: an update of concepts and management recommendations of
European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
doi:10.1186/1756-8722-4-7
Cite this article as: Wongboonma et al.: A single-tube allele specific-
polymerase chain reaction to detect T315I resistant mutation in chronic
myeloid leukemia patients. Journal of Hematology & Oncology 2011 4:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wongboonma et al. Journal of Hematology & Oncology 2011, 4:7
http://www.jhoonline.org/content/4/1/7
Page 7 of 7